As an enzyme replacement therapy (ERT), idursulfase is often prescribed for mucopolysaccharidosis (MPS) II (Hunter syndrome), facilitating the degradation of glycosaminoglycans (GAGs) by replacing the deficient enzyme iduronate-2-sulfatase [14]. Here, IDS is linked to mucopolysaccharidosis type 2.